Pathogenesis and current therapies for non-infectious uveitis.
Pathogenesis and current therapies for non-infectious uveitis.
复制标题
非感染性葡萄膜炎的发病机制和当前治疗方法
DOI：
10.1007/s10238-022-00954-6
复制
发表时间：
2023-08
影响因子：
4.6
通讯作者：
Zhang, Ming
中科院分区：
文献类型：
--
作者：
Wu, Xue;Tao, Mengying;Zhu, Ling;Zhang, Ting;Zhang, Ming
非感染性葡萄膜炎（NIU）是一种具有多种病因的疾病，其特征在于眼部炎症，主要影响工作年龄的人。NIU的准确诊断对于适当的治疗至关重要。治疗的目的是提高视力，减轻眼部炎症，防止复发，避免治疗副作用。目前，皮质类固醇是局部或全身治疗的主要药物。然而，治疗慢性NIU需要重复注射。最近，可以确保治疗药物水平的眼内递送的新的药物递送系统已经被强调。此外，随着免疫抑制剂和生物制剂的发展，可以根据每个患者的需求选择特定的治疗方法。用于治疗NIU的免疫抑制剂包括钙调磷酸酶抑制剂和抗代谢药。然而，全身免疫抑制治疗本身与由于免疫功能抑制引起的不良反应相关。在难治性NIU患者或不能耐受皮质类固醇和免疫抑制剂的患者中，生物制剂已成为替代治疗方法。因此，为了改善NIU患者的预后，应根据对治疗的反应和可能的副作用使用不同的药物来管理NIU。
Non-infectious uveitis (NIU) is a disorder with various etiologies and is characterized by eye inflammation, mainly affecting people of working age. An accurate diagnosis of NIU is crucial for appropriate therapy. The aim of therapy is to improve vision, relieve ocular inflammation, prevent relapse, and avoid treatment side effects. At present, corticosteroids are the mainstay of topical or systemic therapy. However, repeated injections are required for the treatment of chronic NIU. Recently, new drug delivery systems that may ensure intraocular delivery of therapeutic drug levels have been highlighted. Furthermore, with the development of immunosuppressants and biologics, specific therapies can be selected based on the needs of each patient. Immunosuppressants used in the treatment of NIU include calcineurin inhibitors and antimetabolites. However, systemic immunosuppressive therapy itself is associated with adverse effects due to the inhibition of immune function. In patients with refractory NIU or those who cannot tolerate corticosteroids and immunosuppressors, biologics have emerged as alternative treatments. Thus, to improve the prognosis of patients with NIU, NIU should be managed with different drugs according to the response to treatment and possible side effects.
登录
查看更多内容
影响因子：
5
作者：
Alibaz-Oner F;Direskeneli H
通讯作者：
Direskeneli H
影响因子：
4.1
作者：
Becker, MD;Heiligenhaus, A;Fiehn, C
通讯作者：
Fiehn, C
影响因子：
3.3
作者：
Abu El-Asrar, Ahmed M.;Dheyab, Abdulsalam;Opdenakker, Ghislain
通讯作者：
Opdenakker, Ghislain
影响因子：
3.1
作者：
Babu BM;Rathinam SR
通讯作者：
Rathinam SR
影响因子：
3.1
作者：
Agrawal R;Iyer J;Connolly J;Iwata D;Teoh S
通讯作者：
Teoh S